title: Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide.
abstract: During the past few years, the biological functions of macrophage migration inhibitory factor (MIF) have been extensively re-evaluated. This has been found to be protein involved in broad-spectrum pathophysiological states as an inflammatory cytokine, pituitary-derived hormone, and glucocorticoid-induced immunomodulator. In this study, we investigated the involvement of this cytokine in the pathogenesis of lethal liver injury. Injecting a small dose of lipopolysaccharide (LPS) into bacille Calmette-Guerin (BCG)-primed Jcl:ICR mice caused a lethal hepatic injury mimicking fulminant hepatitis, in which 8 of 11 mice died within 48 hours (27% survival rate). Massive necrosis of parenchymal hepatocytes with marked mononuclear cell infiltration was observed by histological examination. Immunohistochemical analysis showed that most of the infiltrating mononuclear cells were Kupffer cells, macrophages, and, to a lesser extent, T cells. In parallel, serum aminotransferase and tumor necrosis factor-alpha (TNF-alpha) levels were increased. When an anti-MIF polyclonal antibody (0.3 mg IgG fraction/mouse) was intraperitoneally injected into mice primed with BCG, it protected them from acute hepatic failure (90% survival rate) with concomitant improvement of histological features. Injection of the antibody also suppressed the up-regulation of TNF-alpha and T-cell infiltration induced by LPS. Taken together, these results suggested that treatment with the anti-MIF antibody suppresses the endotoxin-induced fatal hepatic failure by regulating production of inflammatory cytokines and T-cell infiltration.
authors.affiliation: Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: J
authors.initials: J
authors.lastname: Nishihira
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Todo
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D004926:Escherichia coli; D008070:Lipopolysaccharides / Q000633:toxicity*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017093:Liver Failure / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008263:Macrophage Migration-Inhibitory Factors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000276:immunology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009163:Mycobacterium bovis; D011817:Rabbits; D051381:Rats; D015996:Survival Rate; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D000906:Antibodies; D008070:Lipopolysaccharides; D008263:Macrophage Migration-Inhibitory Factors; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase